Influence of Hydrophobic Ion Pairing on Formulation Performance of Liraglutide in PLGA Microspheres.

The Food and Drug Administration of the United States (USFDA) and the European Medicines Agency (EMA) have approved peptide-based long-acting formulations to manage chronic diseases. However, the formulation of long-acting injectables for hydrophilic drug molecules and peptides remains a persistent challenge due to poor encapsulation and high initial burst release, which increases the complexity of the formulation. In the present research, we formulated long-acting injectable microspheres for liraglutide, a peptide used for managing type 2 DM (Diabetes Mellitus), utilizing a modified solid-oil-water (S/O/W) method.

Monophasic coamorphous sulpiride: a leap in physicochemical attributes and dual inhibition of GlyT1 and P-glycoprotein, supported by experimental and computational insights.

Study aimed to design and development of a supramolecular formulation of sulpiride (SUL) to enhance its solubility, dissolution and permeability by targeting a novel GlyT1 inhibition mechanism. SUL is commonly used to treat gastric and duodenal ulcers, migraine, anti-emetic, anti-depressive and anti-dyspeptic conditions. Additionally, Naringin (NARI) was incorporated as a co-former to enhance the drug's intestinal permeability by targeting P-glycoprotein (P-gp) efflux inhibition.

In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles.

The present investigation aims to develop lumefantrine loaded binary solid lipid nanoparticles (LF-SLNs) to improve its poor and variable oral bioavailability. The oral bioavailability of LF is poor and variable due to its limited aqueous solubility and P-gp mediated efflux occurring in small intestine. LF-SLNs were prepared using binary lipid mixture of stearic acid and caprylic acid stabilized with TPGS (D-alpha tocopheryl polyethylene glycol 1000 succinate) and Poloxamer 188.